madman
Super Moderator
The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with shared decision-making and PSA-testosterone co-monitoring as the foundation of responsible care, as Helen L. Bernie, DO, MPH, outlines in this interview.